Joshua Brody, MD, of the Icahn School of Medicine at Mount Sinai, summarizes important data on passive and active immunotherapy (Abstracts 1213, 1214, 1215, 1216, 1217, 1218).
Harry P. Erba, MD, PhD, of the University of Alabama at Birmingham, discusses phase Ib findings on vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed AML (Abstract 211).
Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145).
Robert E. Marcus, MD, of Kings College Hospital, discusses study findings on obinutuzumab-based induction and maintenance in patients with previously untreated disease (Abstract 6).
Jose F. Leis, MD, PhD, of the Mayo Clinic, and Sagar Lonial, MD, of Emory University, discuss a session on CLL treatment (excluding transplantation): ibrutinib resistance, transformation, and cellular therapy.
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses agents in the pipeline for follicular lymphoma, including drugs targeting the immune microenvironment, novel monoclonal antibodies, and emerging immunotherapeutics.
